Identifying resistance mechanisms of targeted BRAF inhibitors in metastatic melanoma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1072461

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Late-stage melanoma is an aggressive skin cancer for which traditional treatment strategies such as chemotherapy are ineffective. Recently, a new class of targeted drugs (BRAF inhibitors) has become the standard of care for a subset of melanoma patients; however, long term treatment success is complicated by drug resistance. This study will identify the causes of resistance with the purpose to improve targeted drug strategies and increase survival rates for late-stage melanoma patients.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2018

Funding Scheme: Early Career Fellowships

Funding Amount: $379,015.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Genetics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer | functional genomics | melanoma | sequencing | targeted therapy

Related Links